-

Linesight Leads Collaboration of Major Pharmaceutical Companies on Benchmarking Data

Linesight is seeking others to join Merck, AstraZeneca, BMS, Pfizer, GSK, Ipsen, Viatris and Wuxi

LONDON--(BUSINESS WIRE)--Multinational consultancy firm, Linesight, announced today that it is leading a collaboration with the major pharmaceutical companies on benchmarking data. Merck, AstraZeneca, BMS, Pfizer, GSK, Ipsen, Viatris, Wuxi and others are already participating in this global effort to collate capital project benchmarking costs, schedule intelligence and analysis in a central, independent, confidential fashion. Linesight is now seeking others to join this important initiative.

“Connecting the world’s leading life sciences organizations means that we are enabling peer and market alignment by providing valuable cost and schedule intelligence on all major projects. The information is collated in a confidential manner ensuring that the participants receive critical benchmarking data to gauge their investment levels. The more project data we collate the more valuable it will be to the industry at large which is why we are seeking further companies to get involved. This is a hugely significant initiative, and one which will have global impact for many years to come.” said Nigel Barnes, Director of Life Sciences EMEA, Linesight.

Commenting on the initiative, Steve White, Leader of Global Estimating and Control at Merck said “Benchmarking data is essential to gauge the capital effectiveness of our projects both internally and externally with other pharmaceutical companies.”

Steve Townsend, Director Project Controls, Global Capital Projects, GSK also added “As we seek to continuously improve our project scoping and delivery, we must understand how we compare to our peers within the industry. Participating in this program offers us the necessary access to key, comparative data and should provide us with improved confidence.”

To participate in this program please contact lifesciences@linesight.com

ENDS

About Linesight

Linesight is a multinational consultancy firm with over 45 years' experience, providing cost, schedule, program and project management services to a multitude of sectors including Life Sciences, Commercial, Data Centers, High-Tech Industrial, Residential, Hospitality, Healthcare and Retail. Linesight’s specialist project teams, each with specific skills and experience, provide faster project delivery, greater cost efficiency and maximum value for money for their clients. For further information, please visit http://www.linesight.com

Contacts

Cameron Thomas for Linesight
T: (416) 660-9801 E: cameron@verbfactory.com

Linesight


Release Summary
Linesight leads collaboration of major pharmaceutical companies on benchmarking data; Merck, AstraZeneca, BMS, Pfizer, GSK, Ipsen, Viatris and Wuxi
Release Versions

Contacts

Cameron Thomas for Linesight
T: (416) 660-9801 E: cameron@verbfactory.com

More News From Linesight

Recovery Takes Hold as Infrastructure and Renewables Accelerate Canada’s Construction Growth Into 2026, says Linesight

TORONTO--(BUSINESS WIRE)--According to Linesight’s latest Construction Market Insights report, Canada’s construction industry is expected to have rebounded with 2.2% growth in 2025 after two years of contraction. The recovery is led by infrastructure and renewable energy projects, alongside industrial construction gains in chemical and pharmaceutical sectors. From 2026 to 2029, construction output is expected to grow at an average annual rate of 2.8%, driven by major investment in transport, re...

Resilience in the US Construction Industry Projected for 2026 as Mission-Critical Investment Offsets 2025 Slowdown, says Linesight

NEW YORK--(BUSINESS WIRE)--Linesight today released its latest Construction Market Insights report, signaling a resilient outlook for the US construction industry after a softer 2025. While output is projected to have contracted by 2.7% in 2025 following 6.5% growth in 2024, momentum in data centers, transport infrastructure, semiconductors and advanced manufacturing is set to drive steady growth in 2026. Looking ahead, the US construction industry is expected to grow at an average annual rate...

North American Construction Market Forecasts Steady Growth Through 2028 Despite Power and Workforce Constraints, Says Linesight

NEW YORK--(BUSINESS WIRE)--Global construction consultant Linesight has released its latest Construction Market Insights report, revealing that the North American construction industry continues to gain momentum, fueled by mission-critical sectors, despite the uncertainty surrounding US tariffs and global trade. Despite global trade uncertainty and the ongoing impacts of US tariffs, the industry is anticipating steady growth. In 2024, the US construction industry grew by 4.5%, exceeding the ini...
Back to Newsroom